Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.36 |
| ▸ | CHRNG | P07510 | 1/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CHRND | Q07001 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24684153 | 0.86 | KDM1A (0.32) | — | |
| SCHEMBL19706116 | 0.78 | ADRA2A (0.42) | PDK2HDAC4ALDH1A1CYP3A4MAPT | |
| SCHEMBL19871652 | 0.77 | TSHR (0.44) | LMNAPDK2ALDH1A1MAPK1CYP3A4 | |
| SCHEMBL3727746 | 0.77 | KDM1A (0.49) | ACHECHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL14216867 | 0.75 | MAOB (0.38) | ACHESLC6A2SLC6A3LMNA | |
| SCHEMBL14216812 | 0.74 | ALDH1A1 (0.36) | HTR2APDK2ALDH1A1MAPTCYP2C9 | |
| SCHEMBL30572999 | 0.73 | SIGMAR1 (0.46) | ACHEHTR2CHTR2ACHRNA1CHRNG | |
| SCHEMBL2525541 | 0.73 | ADRA2A (0.47) | ACHEHTR2CHTR2ALMNANPSR1 | |
| SCHEMBL21504234 | 0.73 | SIGMAR1 (0.46) | ACHEHTR2CHTR2ACHRNA1CHRNG | |
| SCHEMBL21325311 | 0.73 | HTR2A (0.41) | HTR2CHTR2ASLC6A2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2997029-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1948666-B1 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7511037-B2 | N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511037-B2 | N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070111984-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-7176196-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176196-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176196-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-7157447-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157447-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157447-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060276466-A1 | Bicyclic heterocycles as HIV integrase inhibitors | NAIDU B N | 2006-12-07 | — | — | US | disclosed |
| US-20060199956-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-07 | — | — | US | disclosed |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ACHE 1463/4885HTR2C 4649/4885HTR2A 4359/4885 |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ACHE 1696/4885HTR2C 4651/4885HTR2A 4386/4885 |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ACHE 1696/4885HTR2C 4651/4885HTR2A 4386/4885 |
| US-20060199956-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | ACHE 3850/4885HTR2C 2926/4885HTR2A 3983/4885 |
| US-20070111984-A1 | HIV integrase inhibitors | TYMP, POLN, IMPDH1 | ACHE 3850/4885HTR2C 4122/4885HTR2A 4074/4885 |
| US-20060276466-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | ACHE 3850/4885HTR2C 2926/4885HTR2A 3983/4885 |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | ACHE 3850/4885HTR2C 2926/4885HTR2A 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.